Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies

Area of Science:

• Health Economics
• Clinical Research Methodology

Background:

• Pharmacoeconomic evaluations are crucial for assessing healthcare interventions.
• Data for these evaluations are sourced from randomized clinical trials (RCTs) and real-world effectiveness studies.
• Both study designs have distinct advantages and limitations impacting data quality and applicability.

Purpose of the Study:

• To compare pharmacoeconomic data obtained from RCTs versus real-world effectiveness studies.
• To analyze the implications of study design differences on data collection, bias, and generalizability.
• To guide the selection of appropriate study designs for robust pharmacoeconomic evaluations.

Main Methods:

• Comparative review of study designs: RCTs and real-world effectiveness studies.
• Analysis of design features influencing internal validity and generalizability.
• Examination of data collection, analysis, and interpretation challenges in each design.

Main Results:

• RCTs prioritize internal validity, yielding limited, potentially non-generalizable pharmacoeconomic data.
• Effectiveness studies enhance generalizability to diverse patient populations but may introduce other biases.
• Differences in protocol requirements and patient heterogeneity affect cost estimates and applicability.

Conclusions:

• Choosing between RCTs and effectiveness studies depends on the specific pharmacoeconomic research question.
• Understanding design limitations is key to accurate interpretation of pharmacoeconomic findings.
• Both approaches are valuable, but their respective strengths and weaknesses must be carefully considered.